163 related articles for article (PubMed ID: 27550199)
1. New Screening Criteria Setting on Evaluation of Cytochrome P450 Induction Using HepaRG Cells with Multiplex Branched DNA Technologies in Early Drug Discovery.
Ogasawara A; Torimoto N; Tsuda N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
Drug Metab Lett; 2016; 10(3):152-160. PubMed ID: 27550199
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells.
Ogasawara A; Kato N; Torimoto N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
Drug Metab Lett; 2018; 12(1):14-23. PubMed ID: 29357810
[TBL] [Abstract][Full Text] [Related]
3. An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes.
Halladay JS; Wong S; Khojasteh SC; Grepper S
J Pharmacol Toxicol Methods; 2012; 66(3):270-5. PubMed ID: 22809809
[TBL] [Abstract][Full Text] [Related]
4. Human HepaRG Cells can be Cultured in Hanging-drop Plates for Cytochrome P450 Induction and Function Assays.
Murayama N; Usui T; Slawny N; Chesné C; Yamazaki H
Drug Metab Lett; 2015; 9(1):3-7. PubMed ID: 25600204
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
[TBL] [Abstract][Full Text] [Related]
6. Selective Suppression of CYP3A4 mRNA and Enzyme Activity by Epidermal Growth Factor in Plated Human Hepatocytes.
Zhang JG; Wang D; Ho T; Clark RJ; Stresser DM
Drug Metab Lett; 2017; 11(2):119-127. PubMed ID: 29189189
[TBL] [Abstract][Full Text] [Related]
7. Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2.
Bachmann F; Duthaler U; Meyer Zu Schwabedissen HE; Puchkov M; Huwyler J; Haschke M; Krähenbühl S
Clin Pharmacol Ther; 2021 Jun; 109(6):1505-1516. PubMed ID: 33336382
[TBL] [Abstract][Full Text] [Related]
8. HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics.
Choi JM; Oh SJ; Lee SY; Im JH; Oh JM; Ryu CS; Kwak HC; Lee JY; Kang KW; Kim SK
Arch Pharm Res; 2015; 38(5):691-704. PubMed ID: 25336106
[TBL] [Abstract][Full Text] [Related]
9. The application of HepRG cells in evaluation of cytochrome P450 induction properties of drug compounds.
Andersson TB
Methods Mol Biol; 2010; 640():375-87. PubMed ID: 20645063
[TBL] [Abstract][Full Text] [Related]
10. Establishment of In Silico Prediction Models for CYP3A4 and CYP2B6 Induction in Human Hepatocytes by Multiple Regression Analysis Using Azole Compounds.
Nagai M; Konno Y; Satsukawa M; Yamashita S; Yoshinari K
Drug Metab Dispos; 2016 Aug; 44(8):1390-8. PubMed ID: 27208383
[TBL] [Abstract][Full Text] [Related]
11. Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies.
Kenny JR; Chen L; McGinnity DF; Grime K; Shakesheff KM; Thomson B; Riley R
Xenobiotica; 2008 Dec; 38(12):1500-17. PubMed ID: 18989830
[TBL] [Abstract][Full Text] [Related]
12. A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with β-naphthoflavone, phenobarbital and rifampicin.
Zhang JG; Ho T; Callendrello AL; Crespi CL; Stresser DM
Drug Metab Lett; 2010 Dec; 4(4):185-94. PubMed ID: 20583967
[TBL] [Abstract][Full Text] [Related]
13. Deconvolution of Cytochrome P450 Induction Mechanisms in HepaRG Nuclear Hormone Receptor Knockout Cells.
Preiss LC; Liu R; Hewitt P; Thompson D; Georgi K; Badolo L; Lauschke VM; Petersson C
Drug Metab Dispos; 2021 Aug; 49(8):668-678. PubMed ID: 34035124
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells.
Sugiyama I; Murayama N; Kuroki A; Kota J; Iwano S; Yamazaki H; Hirota T
Xenobiotica; 2016 Sep; 46(9):765-74. PubMed ID: 26711482
[TBL] [Abstract][Full Text] [Related]
15. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.
Kanebratt KP; Andersson TB
Drug Metab Dispos; 2008 Jan; 36(1):137-45. PubMed ID: 17954527
[TBL] [Abstract][Full Text] [Related]
16. In vitro assessment of P450 induction potential of novel chemopreventive agents SR13668, 9-cis-UAB30, and pentamethychromanol in primary cultures of human hepatocytes.
Jackson JP; Kabirov KK; Kapetanovic IM; Lyubimov A
Chem Biol Interact; 2009 May; 179(2-3):263-72. PubMed ID: 19135037
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture.
Badolo L; Jensen B; Säll C; Norinder U; Kallunki P; Montanari D
Xenobiotica; 2015 Feb; 45(2):177-87. PubMed ID: 25183402
[TBL] [Abstract][Full Text] [Related]
18. A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison.
Zhou D; Sunzel M; Ribadeneira MD; Smith MA; Desai D; Lin J; Grimm SW
Br J Clin Pharmacol; 2012 Jul; 74(1):98-108. PubMed ID: 22122233
[TBL] [Abstract][Full Text] [Related]
19. Effect of butylated hydroxytoluene, curcumin, propyl gallate and thiabendazole on cytochrome P450 forms in cultured human hepatocytes.
Price RJ; Scott MP; Giddings AM; Walters DG; Stierum RH; Meredith C; Lake BG
Xenobiotica; 2008 Jun; 38(6):574-86. PubMed ID: 18570159
[TBL] [Abstract][Full Text] [Related]
20. Cryopreserved human hepatocytes as alternative in vitro model for cytochrome p450 induction studies.
Garcia M; Rager J; Wang Q; Strab R; Hidalgo IJ; Owen A; Li J
In Vitro Cell Dev Biol Anim; 2003; 39(7):283-7. PubMed ID: 14599235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
